Celldex Therapeutics Inc.

6 hours ago · benzinga.com

Celldex Therapeutics Inc. (NASDAQ:CLDX) on Tuesday shared topline results from its Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 clinical trials. The studies evaluate barzolvolimab for patients with chronic spontaneous urticaria (CSU) who experience inadequate symptom control using H1-antihistamines, including those who are advanced therapy experienced or refractory.

6 hours ago · zacks.com

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.

10 hours ago · reuters.com

Celldex Therapeutics said on Tuesday its experimental drug for a skin disease met the main and secondary ​goals of two late-stage trials.

1 day ago · defenseworld.net

Celldex Therapeutics (NASDAQ: CLDX - Get Free Report) and Bicycle Therapeutics (NASDAQ: BCYC - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation. Analyst Ratings This is a breakdown of recent

14 days ago · globenewswire.com

HAMPTON, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the upcoming Cantor Global Healthcare Conference on September 10, 2026 at 8:00am ET.

29 days ago · prnewswire.com

NEW YORK, Aug. 24, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Celldex Therapeutics, Inc. (NASDAQ: CLDX) on behalf of the company's shareholders. The investigation seeks to determine whether Celldex Therapeutics's directors breached their fiduciary duties in connection with recent corporate actions.

2 months ago · zacks.com

Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.94 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $0.85 per share a year ago.

2 months ago · zacks.com

Here is how Celldex Therapeutics (CLDX) and Illumina (ILMN) have performed compared to their sector so far this year.

2 months ago · defenseworld.net

Celldex Therapeutics (NASDAQ: CLDX) said a Phase 2 trial of barzolvolimab in prurigo nodularis did not meet its primary or secondary endpoints, prompting the company to discontinue development of the drug in that indication while continuing to focus on ongoing late-stage urticaria studies. Anthony Marucci, Celldex's co-founder, president and chief executive officer, said the company was

2 months ago · seekingalpha.com

Celldex Therapeutics, Inc. (CLDX) Discusses Phase II Barzolvolimab Results in Prurigo Nodularis and Trial Discontinuation Transcript